Osteoarthritis drug may work too well, causing patients to overuse joints
October 5, 2010
Pharmaceutical
Details of a 16-week clinical trial on the osteoarthritis drug tanezumab show the medication offers considerable improvement in the condition of patients with just a few small side effects, according to an article published in a recent issue of the ... Read More
150 Toyota drivers continue to report sudden acceleration every week
October 5, 2010
Consumer Fraud
Toyota says it receives about 150 reports of sudden unintended acceleration every week, with most of the complaints coming through the the company’s customer-service hotline. The good news is that six months ago, the car manufacturer was receiving more than ... Read More
FDA records raise new concerns about Gardasil safety
October 5, 2010
Pharmaceutical
Parents in Virginia are worried following the release of a new report that links the Gardasil vaccine to 16 deaths and nearly 4,000 adverse events. Currently, the vaccine, which protects against four types of human papillomavirus (HPV) linked to cervical ... Read More
FDA’s new rule may discourage switching brand name with generic
October 5, 2010
Pharmaceutical
A new final rule announced last week by the Food and Drug Administration (FDA) may help prevent automatic formulation switching from a brand name drug to a generic by pharmacists and insurance companies. The new rule, which goes into effect in ... Read More
Experimental diabetes drug performs well in clinical trials
October 5, 2010
Pharmaceutical
An experimental new diabetes drug, lixisenatide, combined with Lantus, helped patients better control the level of sugar in their blood, according to results from a phase three clinical trial sponsored by Sanofi-Aventis SA. Lantus is the No. 1 best selling ... Read More
FDA accuses Tylenol maker of not promptly fixing quality problems
October 5, 2010
Product Liability
A Johnson & Johnson manufacturing plant will begin shipping bottles of grape-flavored children’s Tylenol this week as the drug company’s chief executive faces a congressional committee to explain how the once-trusted company could have let its quality standards go so ... Read More